Outlook Therapeutics, Inc. (OTLK)

0.503 -0.01 (-1.37%) USD  |  NASDAQ  |  Jan 23, 16:00
0.5044 0.00 (0.00%) Pre-Market: 20:00
More

Outlook Therapeutics Research and Development Expense (TTM): 33.72M for June 30, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for OTLK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. 95.29M
Amicus Therapeutics, Inc. 142.29M
Neogen Corp. 20.47M
CorMedix, Inc. 12.46M
NovaBay Pharmaceuticals, Inc. --